CRISPR Therapeutics (CRSP) Competitors $55.96 -0.38 (-0.67%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$56.52 +0.56 (+1.00%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, TEVA, and GMABShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Teva Pharmaceutical Industries (TEVA), and Genmab A/S (GMAB). These companies are all part of the "medical" sector. CRISPR Therapeutics vs. Its Competitors Allogene Therapeutics Axsome Therapeutics Beam Therapeutics Editas Medicine KALA BIO Moderna Intellia Therapeutics Vertex Pharmaceuticals Teva Pharmaceutical Industries Genmab A/S CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Is CRSP or ALLO more profitable? Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Allogene Therapeutics N/A -52.98%-41.28% Do insiders & institutionals believe in CRSP or ALLO? 69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate CRSP or ALLO? CRISPR Therapeutics currently has a consensus target price of $71.60, indicating a potential upside of 27.95%. Allogene Therapeutics has a consensus target price of $8.44, indicating a potential upside of 704.23%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk & volatility, CRSP or ALLO? CRISPR Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Which has higher earnings & valuation, CRSP or ALLO? Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M136.41-$366.25M-$5.43-10.31Allogene Therapeutics$20K11,483.33-$257.59M-$1.23-0.85 Does the media prefer CRSP or ALLO? In the previous week, CRISPR Therapeutics had 29 more articles in the media than Allogene Therapeutics. MarketBeat recorded 39 mentions for CRISPR Therapeutics and 10 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.53 beat Allogene Therapeutics' score of -0.18 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 10 Very Positive mention(s) 9 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAllogene Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.12B$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-10.3117.9729.8525.14Price / Sales136.41262.52422.3397.16Price / CashN/A41.8335.9458.58Price / Book2.987.238.125.59Net Income-$366.25M-$54.43M$3.26B$265.48M7 Day Performance-0.23%0.22%0.68%1.22%1 Month Performance2.08%5.59%2.46%0.39%1 Year Performance16.92%9.98%27.99%23.47% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics3.6797 of 5 stars$55.96-0.7%$71.60+27.9%+18.4%$5.12B$37.31M-10.31460Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionALLOAllogene Therapeutics3.0034 of 5 stars$1.14+5.1%$8.44+644.0%-57.5%$246.07MN/A-0.91310AXSMAxsome Therapeutics4.8393 of 5 stars$107.14+4.0%$172.33+60.9%+24.4%$5.27B$432.16M-18.56380Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionBEAMBeam Therapeutics2.7515 of 5 stars$19.27+2.3%$48.75+153.0%-27.0%$1.95B$63.58M-4.20510Earnings ReportAnalyst ForecastAnalyst RevisionEDITEditas Medicine4.24 of 5 stars$2.61+6.8%$4.70+80.4%-39.4%$218.07M$32.31M-0.86230KALAKALA BIO3.4302 of 5 stars$7.41-1.2%$13.00+75.4%+20.1%$47.79M$3.89M-0.9030MRNAModerna4.3276 of 5 stars$27.62+0.0%$45.61+65.1%-67.4%$10.66B$3.06B-3.665,800Trending NewsEarnings ReportAnalyst RevisionNTLAIntellia Therapeutics4.2316 of 5 stars$12.21+6.2%$33.37+173.4%-46.2%$1.27B$45.57M-2.34600News CoverageEarnings ReportVRTXVertex Pharmaceuticals4.9202 of 5 stars$471.47+2.0%$509.89+8.1%-19.4%$121.07B$11.10B-120.276,100Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionTEVATeva Pharmaceutical Industries2.9388 of 5 stars$15.69+2.0%$24.71+57.5%-2.8%$18.01B$16.54B-98.1636,830Positive NewsInsider TradeGMABGenmab A/S3.6719 of 5 stars$21.96+0.8%$37.80+72.2%-14.2%$14.10B$3.12B12.492,682News CoverageShort Interest ↑ Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Axsome Therapeutics Alternatives Beam Therapeutics Alternatives Editas Medicine Alternatives KALA BIO Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vertex Pharmaceuticals Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
